Thus, oHSV-1, EGFR-CAR NK cells, and their combination are capable of selectively targeting and destroying tumor cells of BCBMs and all of them, especially the combination, may have an optimal efficacy in patients with tumor cells expressing EGFR. The gene discussed is EGFR; the disease is neoplasm.